Industry And Regulators Thrash Out Brexit Concerns At Stakeholder Meeting
Executive Summary
Regulators and industry shared their concerns about preparedness, legal uncertainties and the regulatory and supply chain implications of Brexit at a recent stakeholder meeting at the European Medicines Agency.
You may also be interested in...
EMA Redistributes Responsibility For 370 Drugs Currently Overseen By UK
The EMA has completed the reallocation to the EU27 member states of more than 370 centrally authorized drugs for which the UK was rapporteur or co-rapporteur. The move has been necessitated by Brexit, which means the UK will no longer play an active role in new drug evaluations at the EMA.
‘Do Not Rely On The Brexit Transition Period!’ EC Warns Hesitant Pharma Firms
Pharmaceutical companies have been urged by the European Commission to press ahead with their contingency planning for Brexit, amid signs some firms are taking a “wait-and-see” approach.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.